US Patent

US10342780 — Compounds useful as kinase inhibitors

Composition of Matter · Assigned to Loxo Oncology Inc · Expires 2036-12-16 · 11y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel compounds that are tyrosine kinase inhibitors, specifically inhibitors of Bruton's tyrosine kinase (BTK).

USPTO Abstract

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US10342780
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-12-16
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Loxo Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.